Drugs / Human CD19 targeted T Cells Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03720457 | Nov 2018 → Oct 2021 | diffuse large B-cell lymphoma, follicular lymphoma | Hrain Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human CD19 targeted T Cells Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03720457 ↗ |
| Action | Deplete | “CAR-T cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells.” PMID 36536403 ↗ Dec 2022 |
| Modality | Cell therapy | “CAR-T cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells.” PMID 36536403 ↗ Dec 2022 |
| Target | CD19 | “Autologous genetically modified anti-CD19 CAR transduced T cells” NCT03720457 ↗ |